PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of tagLink to Publisher's site
 
Therap Adv Gastroenterol. 2009 July; 2(4 Suppl): 31–35.
PMCID: PMC3002531

Effect of Probiotics on Gastrointestinal Function: Evidence from Animal Models

Abstract

The digestive tract works through a complex net of integrative functions. At the level of the gut, this integration occurs between the immune, neuromotor and endocrine systems, the intestinal barrier and gut luminal contents. Gastrointestinal function is controlled and coordinated by the central nervous system to ensure effective motility, secretion, absorption and mucosal immunity. Thus, it is clear that the gut keeps a tightly regulated equilibrium between luminal stimuli, epithelium, immunity and neurotransmission in order to maintain homeostasis. It follows that perturbations of any of these systems may lead to gut dysfunction. While we acknowledge that the gut—brain axis is crucial in determining coordinated gut function, in this review we will focus on peripheral mechanisms that influence gastrointestinal physiology and pathophysiology. We will discuss the general hypothesis that the intestinal content is crucial in determining what we consider normal gastrointestinal physiology, and consequently that alteration in luminal content by dietary, antibiotic or probiotic manipulation can result in changes in gut function. This article focuses on lessons learned from animal models of gut dysfunction.

Keywords: animal models, probiotics, gastrointestinal physiology

Introduction

Regulation of gastrointestinal (GI) function in vivo is so complex that reductionist systems are often used to dissect and identify specific pathways and therapeutic targets at the molecular level. For example, the effects of components of the intestinal microbiota, probiotics or of pathogenic bacteria can be investigated confidently on intestinal cell lines. Coculture systems can be used to introduce a higher degree of complexity and to investigate additional factors such as immune cells. However, these systems reflect only part of the possible interactions occurring in intact animals. Effects of intestinal bacteria on epithelial cells cannot be isolated from their effects on immune activation, neurotransmission and secre-tomotor responses, all of which will, in turn, impact on the initial stimulus. Previous work in animal models has demonstrated that changes in immune activation in the gut, have an impact in gut neuromotor activity [Barreau et al. 2008; Verma-Gandhu et al. 2007, 2006; Akiho et al. 2007; Vallance et al. 2007; Khan et al. 2005; Schemann et al. 2005; Sharkey and Mawe, 2002; Galeazzi et al. 2001; Barbara et al. 2001]. Work in germ-free (GF) animals has clearly demonstrated that in the absence of an intestinal microbiota, intestinal motility is disrupted. The intervals between phase III fronts of the migrating motor complex (MMC) are prolonged, and upon colonization with a specific pathogen free (SPF) flora, motor patterns are completely normalized [Husebye et al. 1994; Caenepeel et al. 1989]. Interestingly, when GF animals, are colonized with Lactobacilli, Bifidobacteria or Clostridia, motor patterns are normalized, in a similar way as observed after colonization with an SPF flora. However, this does not occur with all species of the intestinal microbiota, and animals that are monocolonized with E. coli exhibit the opposite effects. [Husebye et al. 2001] These studies have introduced the concept of ‘species specificity’ and that effects on gut function obtained with one bacterial species cannot be extrapolated to another. Physiological studies on the role of the intestinal microbiota in maintaining normal GI function, are now supported by molecular work, indicating that indeed, colonization with common commensals can modify the expression of a variety of genes involved not only in immunity and barrier function, but in also in motility and neurotransmission [Hooper et al. 2001].

Peripheral factors in the generation of functional gastrointestinal disorders

Irritable bowel syndrome (IBS) and functional dyspepsia (FD) are prototypical syndromes that constitute functional bowel disorders (FBD). They constitute a heterogeneous clinical entity representing a variety of underlying pathogenetic mechanisms. One particular subgroup, termed postinfective IBS (PI-IBS), refers to functional bowel abnormalities that arise in up to 30% of patients after experiencing an infectious GI episode [Marshall et al. 2007, 2006; Borgaonkar et al. 2006; Rodríguez and Ruigómez, 1999; Bercik et al. 2005; Neal et al. 1997; McKendrick and Read, 1994; Chaudhary and Truelove, 1962]. We have developed a model of PI-IBS using transient Trichinella spiralis infection in mice [Barbara et al. 1997]. In the postinfective state, mice develop motor abnormalities and altered visceral perception. [Bercik et al. 2004]. Analysis of in vivo motility patterns using video fluoroscopy and video image analysis demonstrate an increased incidence of retroperistalsis to up to 40–50% time in previously infected mice, compared to only 20–30% in uninfected controls. Motility abnormalities normalize by day 70 postinfection. However, oral administration of T. spiralis antigen during the postinfective state prolongs motor dysfunction beyond day 70. The same phenomenon is observed in a model of gastroduodenal dysfunction induced by chronic Helicobacter pylori infection. Oral administration of H. pylori antigen after bacterial eradication induces an exacerbation of postinfective abnormalities. [Bercik et al. 2002]. These experiments illustrate the concept that antigen load in the gut lumen influences gut motor function in the postinfective state.

Reversal of GI dysfunction by specific probiotic therapy

These observations in gnotobiotic models and in animal models of postinfective gut dysfunction, taken in conjunction, suggest that oral probiotic therapy may influence the neuromotor apparatus. Therefore, we investigated the effect of different probiotic strains on postinfective gut neuromotor dysfunction. Mice were treated from day 10–21 post-T. spiralis infection with four different probiotic strains. Previously infected mice demonstrated hypercontractility compared to uninfected controls. From the four strains of pro-biotics tested, only one, Lactobacillus paracasei NCC2461 (Nestle Culture Collection, Lausanne, Switzerland) significantly attenuated postinfective muscle hypercontractility, and this was accompanied by decreased expression of inflammatory mediators in the muscle layer, such as COX-2 [Verdú et al. 2004]. This study provided the first evidence that the neuromuscular apparatus could be a target for specific probiotic therapy, and emphasized the problem of extrapolating results with one probiotic strain to another.

We also investigated the effect of probiotic therapy on upper GI dysfunction induced by chronic H. pylori infection. We found that mice infected with H. pylori for 4–6 months developed delayed gastric emptying, increased visceral perception and abnormal 24-hour feeding patterns [Bercik et al. 2009, 2002; Verdú et al. 2008]. After eradication of the infection, previously infected mice still displayed delayed gastric emptying at 2 weeks post-eradication compared to uninfected controls. Delayed gastric emptying normalized by 2 months post-eradication. However, if we administered the probiotics L. rhamnosus R0011 and L. helveticus R0052 (Lacidofil) immediately after H. pylori eradication therapy, gastric function normalized more rapidly. We also identified a persistent abnormality in feeding behavior in previously H. pylori infected mice. During chronic infection, the frequency of eating bouts/ 24h were higher in H. pylori infected mice compared to uninfected controls. Control mice, fed predominantly during night-time but during chronic active infection, consumed smaller amounts of food per bout. Consequently, the total amount of food consumed was not altered and mice did not lose weight [Bercik et al. 2009; Verdú et al. 2008]. This abnormal feeding pattern is reminiscent of dyspeptic behavior. More importantly, abnormal feeding patterns remained abnormal up to 2 months post H. pylori eradication. Probiotic therapy after anti-H. pylori therapy completely normalized feeding behavior 2 months post-eradication [Verdú et al. 2008]. The mechanisms underlying the initiation and maintenance of altered feeding behavior in H. pylori infected mice are likely complex. It may be due to altered gastric mechanosensitivity and increased postprandial cholecystokinin release [Bercik et al. 2009, 2002]. Gastric mechanosensitivity induced by chronic H. pylori infection does not completely return to normal after H. pylori eradication. Although this may be involved in the maintenance of altered feeding patterns, increased tumour necrosis factor (TNF)-α expression, specifically in the median eminence, remains upregulated 2 months post-eradication. Our results suggest that persistent abnormal feeding behavior is maintained, at least in part, by persistently upregulated TNF-a in the CNS. [Bercik et al. 2009]. We are currently investigating the impact of probiotic therapy on presistently upregulated TNF-a expression. These studies provide a basis for the investigation of probiotic effects on postinfective consequences operating outside the GI tract and in the CNS.

In addition to postinfectious models of gut dysfunction, we have examined the impact of changes in gut microbiota, induced deliberately by broad spectrum antibiotic therapy, on visceral perception [Verdú et al. 2006]. Patients receiving antibiotics for nongastrointestinal causes were found to report abdominal sympotms more frequently than those not receiving antibiotics [Maxwell et al. 2002]. Indirect evidence also suggests that the incidence of IBS is higher when the initial infectious episode is treated with antibiotics [Ruigómez et al. 2007]. Although this may relate to the increased severity of the triggering gastroenteritis, taken together the studies suggest a link between antibiotic intake and IBS development. We performed colorectal distensions (CRD) before and immediately after a 10-day treatment with the nonabsorbable antibiotic neomycin, bacitracin and primaricin. CRD were measured again 30 days postantibiotic treatment. CRD responses did not differ when measured at day 10 or 30 compared with day 0. In contrast antibiotic-treated mice exhibited increased CRD responses and visceral perception on day 10 and 30 after of antibiotic treatment compared with day 0.

Analysis of a portion of the intestinal microbiota showed that 10 days after administration of antibiotics, lactobacilli from colonic content or tissue were undetectable. On day 30 lactobacilli populations were still markedly reduced in mice previously treated with antibiotics when compared with placebo-treated controls. Bacteroides decreased significantly on day 10 during antibiotic therapy. On day 30, opportunistic increases in enterobacteria and Bacteroides were observed with respect to control values. These antibiotic-induced changes in the intestinal microbiota were associated with a mild but significant increase in acute inflammatory infiltrate in the colonic mucosa. We then investigated whether specific probiotics improved the increased visceral perception associated with antibiotic administration. But because L. paracasei NCC2461 was sensitive to these antibiotics, we used conditioned L. paracasei medium, devoid of live bacteria. Coadministration of conditioned media from L. paracasei with antibiotics reduced visceral hyper-sensitivity associated with the antibiotic treatment [Verdú et al. 2006]. Despite improvement in visceral hypersensitivity, total lactobacilli populations were undetectable in mice given conditioned media, indicating the underlying mechanism was not related to restoration of lac-tobacilli populations. However, the inflammatory cell activity in colonic samples of conditioned media treated mice also normalized. In addition, increased expression of the sensory neurotrans-mitter, SP, was significantly reduced in the area of the submucous and myenteric plexus in mice treated with antibiotics and supplemented with conditioned media. Other groups using different probiotic strains have also demonstrated an impact of probiotic therapy on visceral and pain perception [Rousseaux et al. 2007; Eutamene et al. 2007]. It is likely that the pathways affected by these specific probiotics differ according to the species and model used.

Conclusions

There are limitations to the extrapolation of results in animal models to humans. Animal models reproduce some aspects of disease patho-genesis and allow exploration of pathways that would be difficult to investigate in humans. Animal models are also useful in the identification of novel therapeutic targets and in the pre-clinical screening of these therapies.

Several important concepts on the potential therapeutic value of probiotics on gut functional disorders have arisen from work in animal models. They have provided proof-of-concept that the motor and neural apparatus are a potential target for orally administered probiotics in gut postinfective dysfunction. Also, that the effect of a specific probiotic will depend not only on the particular species used or combination with other probiotics, but on host factors as well. Some probiotics can reduce the risk of progression to a postinfective functional disorder by interfering with the triggering infection or the inflammatory reaction associated with the initiating infection. Other probiotics may act preferentially on a specific target function (motor, neural, immune or intestinal barrier). The end result will depend on both the probiotic used and the host's characteristics. These concepts are key in the design of clinical studies.

Conflict of interest statement

Dr. E Verdú, Dr. P Bercik and Dr. SM Collins have received grants from Nestle Research Center and Institut Rosell-Lallemand.

Contributor Information

Elena F. Verdú, Department of Medicine, McMaster University, Hamilton, Canada ; ac.retsamcm@eudrev.

Premysl Bercik, Department of Medicine, McMaster University, Hamilton, Canada.

Stephen M. Collins, Department of Medicine, McMaster University, Hamilton, Canada.

References

  • Akiho H., Khan W.I., Al-Kaabi A., Blennerhassett P., Deng Y., Collins S.M. (2007) Cytokine modulation of muscarinic receptors in the murine intestine. Am J Physiol Gastrointest Liver Physiol 293:G250–G255 [PubMed]
  • Barbara G., De Giorgio R., Deng Y., Vallance B., Blennerhassett P., Collins S.M. (2001) Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 120:1729–1736 [PubMed]
  • Barbara G., Vallance B.A., Collins S.M. (1997) Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology 113:1224–1232 [PubMed]
  • Barreau F., Salvador-Cartier C, Houdeau E., Bueno L., Fioramonti J. (2008) Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut 57:582–590 [PubMed]
  • Bercik P., De Giorgio R., Blennerhassett P., Verdú E.F., Barbara G., Collins S.M. (2002) Immune-mediated neural dysfunction in a murine model of chronic H. pylori infection. Gastroenterology 123:1205–1215 [PubMed]
  • Bercik P., Verdú E.F., Collins S.M. (2005) Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 34:235–245, vi–vii [PubMed]
  • Bercik P., Verdú E.F., Foster J.A., Lu J., Scherringa A., Kean I. et al. (2009) Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. Am J Physiol Regul Integr Comp Physiol 296:R587–R594 [PubMed]
  • Bercik P., Wang L., Verdú E.F., Mao Y.K., Blennerhassett P., Khan W.I. et al. (2004) Visceral hyperalgesia and intestinal dysmotlity in a mouse model of post infective gut dysfunction. Gastroenterology 127:179–187 [PubMed]
  • Borgaonkar M.R., Ford D.C., Marshall J.K, Churchill E., Collins S.M. (2006) The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci 51:1026–1032 [PubMed]
  • Caenepeel P., Janssens J., Vantrappen G., Eyssen H., Coremans G. (1989) Interdigestive myoelectric complex in germ-free rats. Dig Dis Sci 34:1180–1184 [PubMed]
  • Chaudhary N.A., Truelove S.C. (1962) The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 31:307–322 [PubMed]
  • Eutamene H., Lamine F., Chabo C, Theodorou V, Rochat F., Bergonzelli G.E. et al. (2007) Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. JNutr 137:1901–1907 [PubMed]
  • Galeazzi F., Lovato P., Blennerhassett P.A., Haapala E.M., Vallance B.A., Collins S.M. (2001) Neural change in Trichinella-infected mice is MHC II independent and involves M-CSF-derived macrophages. Am J Physiol Gastrointest Liver Physiol 281:G151–G158 [PubMed]
  • Hooper L.V, Wong M.H., Thelin A., Hansson L., Falk P.G., Gordon J.I. (2001) Molecular analysis of commensal host-microbial relationships in the intestine. Science 291:881–884 [PubMed]
  • Husebye E., Hellström P.M., Midtvedt T. (1994) Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig Dis Sci 39:946–956 [PubMed]
  • Husebye E., Hellström P.M., Sundler F., Chen J., Midtvedt T. (2001) Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 280:G368–G380 [PubMed]
  • Khan W.I., Motomura Y, Blennerhassett P.A., Kanbayashi H., Varghese A.K., El-Sharkawy R.T. et al. (2005) Disruption of CD40-CD40 ligand pathway inhibits the development of intestinal muscle hypercontractility and protective immunity in nematode infection. Am J Physiol Gastrointest Liver Physiol 288:G15–G22 [PubMed]
  • Marshall J.K., Thabane M., Borgaonkar M.R., James C. (2007) Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 5:457–460 [PubMed]
  • Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M. for the Walkerton Health Study Investigators (2006) Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery, Gastroenterology 131:445–50 [PubMed]
  • Maxwell P.R., Rink E., Kumar D., Mendall M.A. (2002) Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 97:104–108 [PubMed]
  • McKendrick M.W, Read N.W. (1994) Irritable bowel syndrome-post salmonella infection. J Infect 29:1–3 [PubMed]
  • Neal K.R., Hebden J., Spiller R. (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 314:779–782 [PMC free article] [PubMed]
  • Rodriguez L.A., Ruigómez A. (1999) Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 318:565–566 [PMC free article] [PubMed]
  • Rousseaux C, Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L. et al. (2007) Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13:35–37 [PubMed]
  • Ruigómez A., Garćia Rodriguez L.A., Panés J. (2007) Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol 5:465–469 [PubMed]
  • Schemann M., Michel K., Ceregrzyn M., Zeller F., Seidl S., Bischoff S.C. (2005) Human mast cell mediator cocktail excites neurons in human and guinea-pig enteric nervous system. Neurogastroenterol Motil 17:281–289 [PubMed]
  • Sharkey K.A., Mawe G.M. (2002) Neuroimmune and epithelial interactions in intestinal inflammation. Curr Opin Pharmacol 2:669–677 [PubMed]
  • Vallance B.A., Radojevic N., Hogaboam CM., Deng Y., Gauldie J., Collins S.M. (2007) IL-4 gene transfer to the small bowel serosa leads to intestinal inflammation and smooth muscle hyperresponsiveness. Am J Physiol Gastrointest Liver Physiol 292:G385–G394 [PubMed]
  • Verdú E.F., Bercik P., Bergonzelli G., Rochat F., Blennerhasset P., Huang X. et al. (2004) Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of post-infective gut dysfunction. Gastroenterology 127:826–837 [PubMed]
  • Verdú E.F., Bercik P., Huang X., Lu J., Al-Mutawaly N., Sakai H. et al. (2008) The role of luminal factors in the recovery of gastric function and behavioral changes after chronic Helicobacter pylori infection. Am J Physiol Gastrointest Liver Physiol 295:G664–G670 [PubMed]
  • Verdú E.F., Bercik P., Verma-Gandhu M., Huang X.X., Blennerhassett P., Jackson W. et al. (2006) Specific probiotic therapy attenuates antibiotic-induced visceral hypersensitivity in mice. Gut 55:182–190 [PMC free article] [PubMed]
  • Verma-Gandhu M., Bercik P., Motomura Y., Verdú E.F., Khan W.I., Blennerhassett P.A. et al. (2006) CD4+ -T cell modulation of visceral nociception in mice. Gastroenterology 130:1721–1728 [PubMed]
  • Verma-Gandhu M., Verdú E.F., Cohen-Lyons D.P, Collins S.M. (2007) Lymphocyte mediated regulation of beta-endorphin in the myenteric plexus. AmJ Physiol Gastrointest Liver Physiol 292:G344–G348 [PubMed]

Articles from Therapeutic Advances in Gastroenterology are provided here courtesy of SAGE Publications